Status:
COMPLETED
A Study of P38 Inhibitor (4) in Patients With Active Rheumatoid Arthritis (RA) on Stable Methotrexate Therapy
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This 6 arm study will evaluate the efficacy and safety of different doses of P38 Inhibitor (4) in patients with RA currently having an inadequate clinical response to methotrexate. Patients will be ra...
Eligibility Criteria
Inclusion
- adult patients \>=18 years of age;
- active rheumatoid arthritis;
- current inadequate clinical response to methotrexate.
Exclusion
- receiving any other disease-modifying anti-rheumatic drug, with the exception of hydroxychloroquine or chloroquine.
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2008
Estimated Enrollment :
374 Patients enrolled
Trial Details
Trial ID
NCT00316771
Start Date
November 1 2005
End Date
March 1 2008
Last Update
November 2 2016
Active Locations (114)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham, Alabama, United States, 35242
2
Paradise Valley, Arizona, United States, 85253
3
Tucson, Arizona, United States, 85704
4
Tucson, Arizona, United States, 85711